Download our whitepaper,
"Major Depressive Disorder: An alarmingly high failure rate of efficacy endpoints in clinical trials"

What's Inside:
- Key FDA-Approved Pivotal Endpoints for MDD Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for MDD.
- How Diagnostic Criteria for MDD Have Evolved and Impact Research.
- Overcoming Common Pitfalls in MDD Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Major Depressive Disorder
Major Depressive Disorder (MDD) is a prevalent and debilitating mental health condition characterized by persistent feelings of sadness, loss of interest or pleasure in daily activities, and a range of cognitive and physical symptoms that significantly impair daily functioning.
MDD is a leading cause of disability worldwide, affecting individuals across all demographics. While its exact causes are multifactorial, involving genetic, biological, environmental, and psychological factors, effective treatment options—such as psychotherapy, pharmacological interventions, and lifestyle modifications—can greatly improve outcomes.
Advancements in the understanding of MDD have reshaped both clinical practice and research efforts. Clinicians now adopt a personalized treatment approach, considering symptom severity, comorbid conditions, and patient preferences to optimize management strategies.
In research, there is a growing focus on uncovering the neurobiological underpinnings of MDD, exploring novel therapeutic targets, and refining diagnostic tools to enhance early detection and intervention.
Our clinical team has over
120
years of combined experience
Depression costs the global economy an estimated
$1trillion
per year in lost productivity
Depression affects over
260
million
people worldwide
It is estimated that more than
50%
of depression sufferers do not receive appropriate care